Matthew Martin

Matthew Martin has a diverse work experience in the field of medicinal chemistry. Matthew is currently serving as the Senior Director of Medicinal Chemistry at Exo Therapeutics, a role they assumed in February 2023. Prior to this, they held the position of Director of Medicinal Chemistry at the same company from September 2022 to February 2023.

From September 2019 to September 2022, Matthew worked as the Director of Chemistry at H3 Biomedicine.

Before joining H3 Biomedicine, Matthew held multiple roles at FORMA Therapeutics, Inc. Matthew worked as the Director of Medicinal Chemistry from 2018 to 2019, as a Principal Scientist from 2015 to 2018, and as a Senior Scientist from 2012 to 2015.

Matthew's career started at Amgen in 2002, where they held the position of Research Scientist I and Research Scientist II. Matthew eventually became a Senior Scientist, leading a chemistry team and contributing to the discovery of pre-clinical candidates. Matthew'swork involved structure-based design and synthesis of biologically active compounds targeting various molecular targets in oncology, neuroscience, and other areas. Matthew worked at Amgen until 2011.

Before joining Amgen, Matthew worked as a Senior Scientist I at Abbott Bioresearch Center from 2001 to 2002 and as a Scientist at BASF Bioresearch Center from 1999 to 2001.

Overall, Matthew Martin has over 20 years of experience in medicinal chemistry, holding various leadership and research positions at different biotechnology and pharmaceutical companies.

Matthew Martin completed their B.S. degree in Chemistry from Worcester Polytechnic Institute from 1990 to 1994. Matthew then pursued a Ph.D. in Organic Chemistry at the Massachusetts Institute of Technology, where they studied from 1994 to 1999.